| Medical and Health Sciences | Lifetime | 141 | GB 18 | 99.99 |
| Oncology | Lifetime | 19 | GB 1 | 99.97 |
| Pulmonary and Respiratory Medicine | Lifetime | 41 | GB 4 | 99.95 |
| Surgery | Lifetime | 170 | GB 10 | 99.86 |
| Pathology and Forensic Medicine | Lifetime | 68 | GB 9 | 99.73 |
| Cancer Research | Lifetime | 689 | GB 47 | 95.28 |
| Hepatology | Lifetime | 467 | GB 26 | 95.66 |
| Medical Genetics | Lifetime | 661 | GB 43 | 92.81 |
| Gastroenterology | Lifetime | 568 | GB 46 | 86.43 |
| Oncology | 2021-2025 | 383 | GB 13 | 95.74 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 446 | GB 30 | 95.25 |
| Pathology and Forensic Medicine | 2021-2025 | 188 | GB 13 | 94.83 |
| Surgery | 2021-2025 | 912 | GB 63 | 91.59 |
| Cancer Research | 2021-2025 | 396 | GB 17 | 71.86 |
| Medical Genetics | 2021-2025 | 376 | GB 15 | 70.79 |
| Colorectal and Anal Carcinomas | Lifetime | 1 | GB 1 | 99.94 |
| Colorectal Cancer Treatments and Studies | Lifetime | 2 | GB 1 | 99.98 |
| Gastric Cancer Management and Outcomes | Lifetime | 4 | GB 1 | 99.99 |
| Esophageal Cancer Research and Treatment | Lifetime | 3 | GB 1 | 99.88 |
| Cancer Treatment and Pharmacology | Lifetime | 18 | GB 1 | 99.91 |
| Metastasis and carcinoma case studies | Lifetime | 12 | GB 1 | 99.69 |
| Colorectal Cancer Surgical Treatments | Lifetime | 21 | GB 5 | 99.79 |
| Genetic factors in colorectal cancer | Lifetime | 41 | GB 9 | 99.76 |
| Lymphoma Diagnosis and Treatment | Lifetime | 69 | GB 7 | 99.74 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 88 | GB 2 | 99.70 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 52 | GB 3 | 99.57 |
| Lung Cancer Treatments and Mutations | Lifetime | 135 | GB 7 | 99.61 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 92 | GB 2 | 99.57 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 129 | GB 4 | 99.26 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 222 | GB 14 | 99.34 |
| Neuroendocrine Tumor Research Advances | Lifetime | 188 | GB 9 | 99.18 |
| Cancer Genomics and Diagnostics | Lifetime | 346 | GB 25 | 99.34 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 62 | GB 3 | 99.06 |
| Viral-associated cancers and disorders | Lifetime | 180 | GB 13 | 98.85 |
| Multiple and Secondary Primary Cancers | Lifetime | 135 | GB 7 | 98.30 |
| Cancer Research and Treatments | Lifetime | 337 | GB 19 | 98.02 |
| Cancer therapeutics and mechanisms | Lifetime | 366 | GB 24 | 98.06 |
| Nausea and vomiting management | Lifetime | 131 | GB 11 | 97.98 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 669 | GB 48 | 97.80 |
| Lung Cancer Research Studies | Lifetime | 772 | GB 32 | 97.49 |
| Colorectal Cancer Screening and Detection | Lifetime | 829 | GB 84 | 97.20 |
| HER2/EGFR in Cancer Research | Lifetime | 703 | GB 37 | 97.18 |
| Multiple Myeloma Research and Treatments | Lifetime | 697 | GB 41 | 96.66 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 775 | GB 46 | 89.88 |
| Chemotherapy-related skin toxicity | Lifetime | 416 | GB 19 | 88.66 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 872 | GB 37 | 87.95 |
| Pathogenesis and Treatment of Hiccups | Lifetime | 246 | GB 26 | 79.03 |
| Lymphadenopathy Diagnosis and Analysis | Lifetime | 235 | GB 12 | 61.77 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 233 | GB 8 | 97.83 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 162 | GB 2 | 97.89 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 302 | GB 16 | 97.12 |
| Genetic factors in colorectal cancer | 2021-2025 | 218 | GB 14 | 95.28 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 448 | GB 22 | 92.77 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 459 | GB 22 | 79.96 |
